You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bazedoxifene acetate; estrogens, conjugated and what is the scope of patent protection?

Bazedoxifene acetate; estrogens, conjugated is the generic ingredient in one branded drug marketed by Wyeth Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bazedoxifene acetate; estrogens, conjugated has twenty-two patent family members in twenty countries.

Two suppliers are listed for this compound.

Summary for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
International Patents:22
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Clinical Trials: 4
DailyMed Link:BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Generic Entry Date for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pfizer
Wyeth is now a wholly owned subsidiary of PfizerPhase 1

See all BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED clinical trials

Pharmacology for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

US Patents and Regulatory Information for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Country Patent Number Title Estimated Expiration
Japan 2009035535 CRYSTALLINE POLYMORPH OF BAZEDOXIFENE ACETATE ⤷  Sign Up
Singapore 151331 CRYSTALLINE POLYMORPH OF A BAZEDOXIFENE ACETATE ⤷  Sign Up
El Salvador 2008002080 POLIMORFO CRISTALINO DE ACETATO DE BAZEDOXIFENO REF. WYTH0084-504 (AM101551) ⤷  Sign Up
Canada 2561010 CORPS POLYMORPHE CRISTALLIN DE BASEDOXIFENE ACETATE (CRYSTALLINE POLYMORPH OF A BAZEDOXIFENE ACETATE) ⤷  Sign Up
Russian Federation 2006132180 КРИСТАЛЛИЧЕСКИЙ ПОЛИМОРФ БАЗЕДОКСИФЕН АЦЕТАТА ⤷  Sign Up
Norway 20065052 ⤷  Sign Up
Guatemala 200500078 POLIMORFO CRISTALINO DE ACETATO DE BAZEDOXIFENO ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0802183 SPC/GB09/045 United Kingdom ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
0802183 2009/028 Ireland ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
0802183 09C0048 France ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/09/511/001 DU 20090417; REGISTRATION NO/DATE AT EEC: EU/1/09/511/001-004 DU 20090417
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.